Source:http://linkedlifedata.com/resource/pubmed/id/19223770
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2009-5-6
|
| pubmed:abstractText |
Endostatin can inhibit tumor growth by blocking angiogenesis, whereas tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) may function as a soluble cytokine to selectively kill cancer cells without toxicity to most normal cells. To establish the combined anti-tumor therapeutic effect of endostatin and soluble TRAIL (sTRAIL), we performed intra-tumoral human endostatin and sTRAIL gene transfer using plasmid pVAX1 as a vector in a nude mouse model of human liver cancer. For subcutaneously inoculated human BEL7402 cancer, co-expression of both transgenes conferred marked anti-tumor activity with a significant reduction in tumor vessel density and an increase in apoptotic rates, which was accompanied with a strong activation of caspase-3. Importantly, combination therapy employing one-half dose of endostatin and sTRAIL plasmids was more effective than single endostatin or sTRAIL therapy. These results indicate that a pVAX1-mediated combinatorial antiangiogenic and proapoptotic gene therapy approach involving endostatin and sTRAIL can be an effective novel form of treatment for human liver cancer.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1555-8576
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
466-73
|
| pubmed:meshHeading |
pubmed-meshheading:19223770-Animals,
pubmed-meshheading:19223770-Apoptosis,
pubmed-meshheading:19223770-Blotting, Western,
pubmed-meshheading:19223770-COS Cells,
pubmed-meshheading:19223770-Carcinoma, Hepatocellular,
pubmed-meshheading:19223770-Cell Line,
pubmed-meshheading:19223770-Cell Line, Tumor,
pubmed-meshheading:19223770-Cercopithecus aethiops,
pubmed-meshheading:19223770-Endostatins,
pubmed-meshheading:19223770-Flow Cytometry,
pubmed-meshheading:19223770-Gene Therapy,
pubmed-meshheading:19223770-Humans,
pubmed-meshheading:19223770-In Situ Nick-End Labeling,
pubmed-meshheading:19223770-Liver Neoplasms, Experimental,
pubmed-meshheading:19223770-Mice,
pubmed-meshheading:19223770-Mice, Inbred BALB C,
pubmed-meshheading:19223770-Mice, Nude,
pubmed-meshheading:19223770-Neovascularization, Pathologic,
pubmed-meshheading:19223770-Plasmids,
pubmed-meshheading:19223770-TNF-Related Apoptosis-Inducing Ligand,
pubmed-meshheading:19223770-Transfection,
pubmed-meshheading:19223770-Treatment Outcome,
pubmed-meshheading:19223770-Tumor Burden,
pubmed-meshheading:19223770-Xenograft Model Antitumor Assays
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice.
|
| pubmed:affiliation |
Department of Pharmacology, Medical School of Shandong University, Jinan, China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|